Stonebridge Capital Management’s Trinity Biotech TRIB Stock Holding History

Stonebridge Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-111	Closed	-$219K	–	139
2016 Q3	$219K	Sell	111 -57	-34%	-$106K	0.09%	106
2016 Q2	$286K	Sell	168 -43	-20%	-$72.7K	0.13%	91
2016 Q1	$369K	Buy	211 +5	+2%	+$7.96K	0.16%	107
2015 Q4	$363K	Sell	206 -80	-28%	-$142K	0.15%	113
2015 Q3	$491K	Sell	286 -21	-7%	-$50.7K	0.22%	84
2015 Q2	$831K	Buy	307 +62	+25%	+$161K	0.34%	60
2015 Q1	$708K	Buy	245 +173	+240%	+$480K	0.29%	71
2014 Q4	$190K	Sell	72 -108	-60%	-$279K	0.07%	171
2014 Q3	$493K	Buy	180 +95	+112%	+$309K	0.19%	104
2014 Q2	$295K	Buy	+85	New	+$302K	0.11%	144

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Stonebridge Capital Management's TRIB Position: Q4 2016 in Review

Stonebridge Capital Management sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 111 shares — an estimated $219K sold.

Stonebridge Capital Management first reported a position in TRIB in Q2 2014 and held it in 10 quarters. The position peaked at $831K in Q2 2015. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

Stonebridge Capital Management reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
Stonebridge Capital Management sold 111 Trinity Biotech shares in Q4 2016, an estimated $219K.
Stonebridge Capital Management first reported a position in Trinity Biotech in Q2 2014 and held it in 10 quarters.
Stonebridge Capital Management's Trinity Biotech position peaked at $831K in Q2 2015.
71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Stonebridge Capital Management's 13F filing for Q4 2016, filed 24 Jan 2017.